<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A8E64194-968B-4463-A037-61C20E48F8BC"><gtr:id>A8E64194-968B-4463-A037-61C20E48F8BC</gtr:id><gtr:firstName>R</gtr:firstName><gtr:surname>Tascon-Ferero</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117562213"><gtr:id>1C039F50-79C2-4B43-95B0-9BE834B40AD4</gtr:id><gtr:title>Cellular and molecular mechanisms involved in the induction of protective immunity against mycobacteria</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117562213</gtr:grantReference><gtr:abstractText>Tuberculosis continues to be a major health problem world-wide; there are several limitations in the effectiveness of the existing vaccine and the continuous emergence of multiple drug-resistant strains of M. tuberculosis represent a serious threat to public health. The main objective of our work is to investigate the principal mechanisms involved in the induction of an effective immune response against tuberculosis. Our studies should provide important information for the development of new vaccines against tuberculosis.</gtr:abstractText><gtr:technicalSummary>Tuberculosis kills more than 3 million people world-wide and continues to be a major problem to human health. We are investigating the cellular and molecular mechanisms involved in the induction of anti-mycobacterial protective immunity following the infection or following anti-mycobacterial vaccination. We hope to develop new approaches for preventing this disease.||Ongoing work focuses on the role of dendritic cells and the priming of specific protective T cell responses. We are characterising several aspects of the interaction between dendritic cells and M. tuberculosis including the molecular mechanisms associated with the activation of these cells in response to the infection and the processing and presentation of individual antigens to T cells. ||Our work will study changes in dendritic cells gene expression using genetic microarrays and evaluate quantitatively the presentation of individual antigens to T cells. We demonstrated that vaccination of mice with dendritic cells infected with M.tuberculosis or with several polinucleotide DNA vectors expressing individual mycobacterial genes, resulted in effective priming of protective T cells in vivo; a further objective of this project will focus in studying different vaccination strategies aiming to boost the immune responses obtained. We will use different strains of mice including some with specific gene mutations and we will characterise quantitatively the specific T cell responses using ELISPOT and intracytoplasmic cytokine analysis. ||Our studies will provide important information for the development of new vaccines for the control of tuberculosis and related diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2006-09-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2000-07-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>379451</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MC_U117562213</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>